Patents by Inventor Aki Nakatani
Aki Nakatani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230357386Abstract: Provided is an anti-EphA4 antibody capable of binding to EphA4 and enhancing the cleavage of EphA4, and a pharmaceutical composition comprising the antibody as an active ingredient. The anti-EphA4 antibody comprises a heavy chain comprising a heavy chain CDR1 of SEQ ID NO: 30; a heavy chain CDR2 of SEQ ID NO: 31; and a heavy chain CDR3 of SEQ ID NO: 32; and a light chain comprising a light chain CDR1 of SEQ ID NO: 33; a light chain CDR2 of SEQ ID NO: 34; and a light chain CDR3 of SEQ ID NO: 35, or a heavy chain comprising a heavy chain CDR1 of SEQ ID NO: 42; a heavy chain CDR2 of SEQ ID NO: 31; and a heavy chain CDR3 of SEQ ID NO: 43; and a light chain comprising a light chain CDR1 of SEQ ID NO: 44; a light chain CDR2 of SEQ ID NO: 34; and a light chain CDR3 of SEQ ID NO: 35.Type: ApplicationFiled: December 22, 2021Publication date: November 9, 2023Inventors: Tomomi KAWAKATSU, Akio YAMADA, Aki NAKATANI, Eiji INOUE
-
Patent number: 11136400Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.Type: GrantFiled: January 8, 2021Date of Patent: October 5, 2021Assignee: Eisai R&D Management Co., Ltd.Inventors: Eiji Inoue, Akio Yamada, Tomomi Kawakatsu, Toshio Imai, Maki Deguchi, Aki Nakatani
-
Patent number: 11034769Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.Type: GrantFiled: January 8, 2021Date of Patent: June 15, 2021Assignee: Eisai R&D Management Co., Ltd.Inventors: Eiji Inoue, Akio Yamada, Tomomi Kawakatsu, Toshio Imai, Maki Deguchi, Aki Nakatani
-
Publication number: 20210171644Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.Type: ApplicationFiled: January 8, 2021Publication date: June 10, 2021Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Eiji INOUE, Akio YAMADA, Tomomi KAWAKATSU, Toshio IMAI, Maki DEGUCHI, Aki NAKATANI
-
Patent number: 10947313Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.Type: GrantFiled: June 29, 2020Date of Patent: March 16, 2021Assignee: Eisai R&D Management Co., Ltd.Inventors: Eiji Inoue, Akio Yamada, Tomomi Kawakatsu, Toshio Imai, Maki Deguchi, Aki Nakatani
-
Publication number: 20210002378Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.Type: ApplicationFiled: June 29, 2020Publication date: January 7, 2021Inventors: Eiji INOUE, Akio YAMADA, Tomomi KAWAKATSU, Toshio IMAI, Maki DEGUCHI, Aki NAKATANI
-
Patent number: 10428140Abstract: It is intended to provide an anti-EphA4 antibody or an EphA4-binding fragment thereof which is capable of binding to EphA4 and inhibiting the binding between EphA4 and its ligand, and a pharmaceutical composition comprising the anti-EphA4 antibody or the EphA4-binding fragment thereof as an active ingredient. A mouse anti-EphA4 antibody having binding affinity for EphA4 was obtained, and the sequences of complementarity-determining regions (CDRs) of the mouse anti-EphA4 antibody were identified. This allowed for preparation of a humanized antibody comprising the CDR sequences of the mouse anti-EphA4 antibody in heavy chain variable region and light chain variable region.Type: GrantFiled: September 6, 2016Date of Patent: October 1, 2019Assignee: Eisai R&D Management Co., Ltd.Inventors: Ryota Taguchi, Toshio Imai, Eiji Inoue, Akio Yamada, Aki Nakatani, Toshifumi Hirayama, Yuichi Ono, Shunsuke Ito
-
Publication number: 20190077860Abstract: It is intended to provide an anti-EphA4 antibody or an EphA4-binding fragment thereof which is capable of binding to EphA4 and inhibiting the binding between EphA4 and its ligand, and a pharmaceutical composition comprising the anti-EphA4 antibody or the EphA4-binding fragment thereof as an active ingredient. A mouse anti-EphA4 antibody having binding affinity for EphA4 was obtained, and the sequences of complementarity-determining regions (CDRs) of the mouse anti-EphA4 antibody were identified. This allowed for preparation of a humanized antibody comprising the CDR sequences of the mouse anti-EphA4 antibody in heavy chain variable region and light chain variable region.Type: ApplicationFiled: September 6, 2016Publication date: March 14, 2019Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Ryota Taguchi, Toshio Imai, Eiji Inoue, Akio Yamada, Aki Nakatani, Toshifumi Hirayama, Yuichi Ono, Shunsuke Ito